Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.33 |
| ▸ | FABP4 | P15090 | 3/20 | 0.33 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.33 |
| ▸ | GLS | O94925 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10877742 | 0.84 | MME (0.36) | MMECNR2ALDH1A1CXCR2FABP4 | |
| SCHEMBL11603247 | 0.84 | MME (0.41) | MMEKDM4EHSD17B10 | |
| SCHEMBL10876885 | 0.81 | CYP1A2 (0.44) | MMEALDH1A1CXCR2 | |
| SCHEMBL10883519 | 0.80 | CXCR2 (0.33) | MMETSHRCNR2ALDH1A1CXCR2 | |
| SCHEMBL7229443 | 0.80 | CNR2 (0.33) | MMECNR2ALDH1A1CXCR2FABP4 | |
| SCHEMBL5101577 | 0.79 | ALDH1A1 (0.36) | CNR2ALDH1A1CXCR2FABP4FABP5 | |
| SCHEMBL9752273 | 0.78 | CYP1A2 (0.35) | ALDH1A1CXCR2FABP4FABP5 | |
| SCHEMBL1403838 | 0.75 | PYGL (0.33) | CNR2ALDH1A1CXCR2FABP4FABP5 | |
| SCHEMBL4416357 | 0.75 | ECE1 (0.45) | MMEALDH1A1FABP4FABP5 | |
| SCHEMBL1403840 | 0.75 | PYGL (0.33) | CNR2ALDH1A1CXCR2FABP4FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106216-B2 | Process for the preparation of Irbesartan | AUROBINDO PHARMA LTD. (IN) | 2012-01-31 | — | — | US | disclosed |
| US-20100056797-A1 | Process for the Preparation of Irbesartan | AUROBINDO PHARMA LTD (IN) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056797-A1 | Process for the Preparation of Irbesartan | AGTR1, REN, AGTR2 | MME 39/4885MEN1 1645/4885TSHR 781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.